Literature DB >> 1380094

Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.

R Q Warren1, S A Anderson, W M Nkya, J F Shao, C W Hendrix, G P Melcher, R R Redfield, R C Kennedy.   

Abstract

Sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals from the United States and Tanzania were examined for antibody reactivity to four synthetic peptides which corresponded to the principal neutralizing determinant from the V3 region of HIV-1 gp120. We observed that the majority of sera from both countries contained antibodies reactive with a V3 peptide whose sequence is based on that of the HIV-1 MN isolate. We were unable to establish a relationship between the presence of V3-reactive antibodies, as measured by enzyme-linked immunosorbent assay and neutralization of homologous HIV-1 isolates, in sera from either the United States or Tanzania. We observed that some sera which contained high antibody titers to the V3 peptides failed to neutralize HIV-1, while others with no antibody reactivity to the panel of V3 peptides exhibited in vitro neutralizing activity. These results suggest that neutralizing epitopes exist outside the V3 loop and that the presence of V3-reactive antibodies in sera does not imply in vitro neutralization of the homologous HIV-1 isolate. In addition, it appears that the V3 loop may consist of both neutralizing and nonneutralizing epitopes. The identification of neutralizing as well as nonneutralizing epitopes will be important for the design of potential HIV-1 vaccines.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Americas; Antibodies--analysis; Biology; Clinical Research; Data Analysis; Developed Countries; Developing Countries; Diseases; Eastern Africa; English Speaking Africa; Examinations And Diagnoses; Hiv Infections; Immunity; Immunologic Factors; In Vitro; Laboratory Examinations And Diagnoses; Laboratory Procedures; Measurement; North America; Northern America; Physiology; Proteins; Research Methodology; Tanzania; United States; Viral Diseases

Mesh:

Substances:

Year:  1992        PMID: 1380094      PMCID: PMC289073     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur.

Authors:  S Wain-Hobson; J P Vartanian; M Henry; N Chenciner; R Cheynier; S Delassus; L P Martins; M Sala; M T Nugeyre; D Guétard
Journal:  Science       Date:  1991-05-17       Impact factor: 47.728

2.  Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus.

Authors:  J W Gnann; J A Nelson; M B Oldstone
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

3.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

Authors:  B R Starcich; B H Hahn; G M Shaw; P D McNeely; S Modrow; H Wolf; E S Parks; W P Parks; S F Josephs; R C Gallo
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

4.  Antibodies from human immunodeficiency virus-infected individuals bind to a short amino acid sequence that elicits neutralizing antibodies in animals.

Authors:  W R Kenealy; T J Matthews; M C Ganfield; A J Langlois; D M Waselefsky; S R Petteway
Journal:  AIDS Res Hum Retroviruses       Date:  1989-04       Impact factor: 2.205

5.  Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping.

Authors:  L D Papsidero; M Sheu; F W Ruscetti
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

6.  Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.

Authors:  G J LaRosa; J P Davide; K Weinhold; J A Waterbury; A T Profy; J A Lewis; A J Langlois; G R Dreesman; R N Boswell; P Shadduck
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

7.  C-terminal fragments of gp120 and synthetic peptides from five HTLV-III strains: prevalence of antibodies to the HTLV-III-MN isolate in infected individuals.

Authors:  Y Devash; T J Matthews; J E Drummond; K Javaherian; D J Waters; L O Arthur; W A Blattner; J R Rusche
Journal:  AIDS Res Hum Retroviruses       Date:  1990-03       Impact factor: 2.205

8.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.

Authors:  J Goudsmit; C Debouck; R H Meloen; L Smit; M Bakker; D M Asher; A V Wolff; C J Gibbs; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

9.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

Authors:  J R Rusche; K Javaherian; C McDanal; J Petro; D L Lynn; R Grimaila; A Langlois; R C Gallo; L O Arthur; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

10.  Use of a resin-bound synthetic peptide for identifying a neutralizing antigenic determinant associated with the human immunodeficiency virus envelope.

Authors:  R C Kennedy; G R Dreesman; T C Chanh; R N Boswell; J S Allan; T H Lee; M Essex; J T Sparrow; D D Ho; P Kanda
Journal:  J Biol Chem       Date:  1987-04-25       Impact factor: 5.157

View more
  11 in total

1.  The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain.

Authors:  M Schreiber; C Wachsmuth; H Müller; S Odemuyiwa; H Schmitz; S Meyer; B Meyer; J Schneider-Mergener
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

2.  The "V3" domain is a determinant of simian immunodeficiency virus cell tropism.

Authors:  F Kirchhoff; K Mori; R C Desrosiers
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

3.  Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.

Authors:  M Schreiber; H Petersen; C Wachsmuth; H Müller; F T Hufert; H Schmitz
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

Review 4.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

5.  Serologic evaluation of human immunodeficiency virus type 1-infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolates.

Authors:  R Q Warren; M T Wong; G P Melcher; S P Blatt; P Cahn; H Perez; I Zapiola; M B Bouzas; G Muchinik; S A Anderson
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

6.  Simple enzyme immunoassay for titration of antibodies to the CD4-binding site of human immunodeficiency virus type 1 gp120.

Authors:  I Turbica; M Posner; C Bruck; F Barin
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

7.  Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.

Authors:  D C Bou-Habib; G Roderiquez; T Oravecz; P W Berman; P Lusso; M A Norcross
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

8.  Presence of neutralizing antibodies to heterologous human immunodeficiency virus type 1 isolates in sera of infected individuals is not predictive of rate of disease progression.

Authors:  R Q Warren; M T Wong; G P Melcher; S P Blatt; I Zapiola; M B Bouzas; G Muchinik; S A Anderson; R C Kennedy
Journal:  Clin Diagn Lab Immunol       Date:  1995-07

9.  Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein.

Authors:  H Zaghouani; S A Anderson; K E Sperber; C Daian; R C Kennedy; L Mayer; C A Bona
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-17       Impact factor: 11.205

10.  Anti-V3 antibody reactivity correlates with clinical stage of HIV-1 infection and with serum neutralizing activity.

Authors:  E Fenouillet; N Blanes; A Benjouad; J C Gluckman
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.